INSP▲
Inspire Medical Systems launches Project Horizon restructuring, raises full-year revenue guidance
Inspire Medical Systems is implementing a strategic shift called Project Horizon to stabilize its growth trajectory following significant coding and reimbursement disruptions for its Inspire V system. The company reported second-quarter revenue of $200.6 million, a 7.6% decrease, with an estimated $40 million adverse impact from coding and reimbursement challenges. Despite the headwinds, management raised its full-year 2026 revenue guidance to a range of $835 million to $875 million, citing improving trends in prior authorization submissions and favorable proposed 2027 facility reimbursement rates from CMS. Project Horizon is expected to create $30 million of annualized growth investment capacity through organizational streamlining and supply chain optimization, with pretax restructuring charges of $20 million to $25 million, approximately 90% of which will be recognized in the third quarter. The company also reported adjusted diluted earnings per share of $0.14 and a gross margin of 85.5%, driven by a higher sales mix of the Inspire V system.
The Motley Fool·16dRead more ▾
Inspire Medical Shares Surge 28.1% in a Month on Earnings Beat and Raised Guidance
Inspire Medical Systems shares have gained 28.1% in the past month, raising the question of whether improving earnings expectations can support further upside. The rally follows a second-quarter adjusted earnings beat of 14 cents per share versus a consensus estimate for a loss of 22 cents, along with revenues of $200.6 million that exceeded expectations despite a 7.6% year-over-year decline. Management raised its 2026 revenue outlook to $835-$875 million and increased adjusted earnings guidance to $1.05-$1.45 per share, while the Zacks Consensus Estimate for 2026 earnings rose 34.7% over the past four weeks. A higher sales mix of Inspire V systems lifted gross margin 150 basis points to 85.5%, though reimbursement friction from coding challenges and the WISeR prior authorization program reduced quarterly revenues by approximately $40 million and is expected to have a $120-$130 million full-year impact. INSP trades at about 2.1 times forward 12-month sales, below its five-year median of 7.1 times and the medical information systems industry's 5.1 times multiple, but further gains likely require clearer evidence of normalizing procedure volumes and revenues.
Zacks Investment Research·21dRead more ▾
Inspire Medical returns to profit in Q2, raises full-year 2026 revenue outlook
Inspire Medical Systems returned to profitability in the second quarter, reporting net earnings of $0.3 million, or $0.01 per share, compared with a net loss of $3.6 million, or $0.12 per share, a year earlier. Revenue for the quarter decreased to $200.6 million from $217.1 million. For the first half of 2026, revenue declined to $405.2 million from $418.4 million, and the net loss widened to $11.0 million, or $0.38 per share, from $0.6 million, or $0.02 per share. The company raised its full-year 2026 revenue guidance to a range of $835 million to $875 million and now expects an adjusted operating margin of 4 percent to 6 percent, with adjusted earnings per share between $1.05 and $1.45. Shares rose 12.05 percent in after-hours trading.
RTTNews·23dRead more ▾
INSP▲
Inspire Medical Systems appoints Michael H. Carrel to its Board of Directors
Inspire Medical Systems has appointed seasoned medical device executive Michael H. Carrel to its Board of Directors, effective July 20. Carrel has served as President, Chief Executive Officer, and a director of AtriCure since November 2012, during which time AtriCure grew from $82 million in revenue in 2013 to $535 million in 2025 while helping more than one million patients. He also served as Chairman of the Board of Directors of Axonics from 2019 through 2024, until its sale to Boston Scientific Corporation. Inspire Medical Systems is a medical technology company focused on minimally invasive solutions for obstructive sleep apnea, and its proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology for moderate to severe obstructive sleep apnea.
GlobeNewswire·30dRead more ▾
INSP▼
Johnson Fistel Investigates Charter, Inspire Medical, Firefly Aerospace, and Quantum for Fiduciary Breaches
Johnson Fistel, PLLP is investigating potential claims on behalf of long-term shareholders of Charter Communications, Inspire Medical Systems, Firefly Aerospace, and Quantum Corporation against certain officers and directors for alleged breaches of fiduciary duty. Shareholders who have held shares continuously since prior to specified dates may seek corporate governance reforms, return of funds, and a court-approved incentive award at no cost. The investigations stem from pending securities class action complaints alleging that each company made materially false and misleading statements or failed to disclose material adverse facts, leading to investor losses when the truth emerged. For Charter Communications, the allegations involve downplaying the impact of the end of the Federal Communications Commission’s Affordable Connectivity Program on Internet customer trends and earnings. Inspire Medical is accused of overstating demand and readiness for its Inspire V sleep apnea device launch while concealing surplus inventory and incomplete training and billing preparations. Firefly Aerospace allegedly overstated demand for its Spacecraft Solutions and the viability of its Alpha rocket program in connection with its initial public offering, with a subsequent rocket stage loss further impacting the stock. Quantum Corporation is alleged to have improperly recognized revenue, necessitating a restatement of financial statements for the fiscal third quarter ended December 31, 2024.
GlobeNewswire·49dRead more ▾
INSP▼
StockStory flags OSI Systems as a Russell 2000 buy, warns on Sabre and Inspire Medical
StockStory highlights OSI Systems as a Russell 2000 stock to target this week, citing its 10.9% annual revenue growth over the last two years and 14.5% annual earnings per share growth over five years, while flagging Sabre and Inspire Medical Systems as facing challenges. Sabre is weighed down by sluggish total bookings, cash burn, and a high net-debt-to-EBITDA ratio of 7 times, while Inspire Medical contends with a smaller revenue base of 915.2 million dollars and a projected 8% sales decline over the next 12 months. OSI Systems, with a market cap of 3.81 billion dollars, trades at 20 times forward price-to-earnings, compared to Sabre at 7.1 times forward enterprise-value-to-EBITDA and Inspire Medical at 49.1 times forward price-to-earnings.
StockStory·49dRead more ▾
INSP▼
Oscar Health Touted as Top Pick While Inspire Medical and IQVIA Are Flagged for Caution
StockStory highlights Oscar Health as a healthcare stock with impressive fundamentals while recommending caution on Inspire Medical Systems and IQVIA. Oscar Health, with a market cap of $8.71 billion, posted annual revenue growth of 42.6% over the last two years and EPS compounding at 31.5% annually over four years, alongside a free cash flow margin expansion of 19.9 percentage points. In contrast, Inspire Medical Systems faces an estimated 8% sales decline and trades at 42.3x forward P/E on a $1.22 billion market cap, while IQVIA's 5.1% annual revenue growth and stagnant free cash flow margin raise concerns, with shares at $167.81 and a 12.8x forward P/E.
StockStory·64dRead more ▾
Biotech & Genomic Medicine▲
Inspire Medical Systems Highlights New OSA Data and PREDICTOR Study at SLEEP 2026
Inspire Medical Systems presented new clinical data, technology advancements, and cardiovascular outcomes research at SLEEP 2026. The company showcased its next-generation Inspire V system, closed-loop hypoglossal nerve stimulation therapy, and the Inspire SleepSync remote patient management platform. A secondary analysis of the STAR trial showed significant reductions in hypoxic burden and improvements in daytime sleepiness, even among 50% of apnea-hypopnea index non-responders. Another study comparing hypoglossal nerve stimulation and CPAP therapy in matched groups of 3,525 patients each demonstrated significantly lower rates of several cardiovascular and respiratory complications. The PREDICTOR study identified body mass index and neck circumference as predictors of complete concentric collapse, suggesting some patients may be screened for Inspire eligibility without drug-induced sleep endoscopy. Final results from a study of the Inspire V system showed a 20.4% reduction in implant time, a reduction in mean AHI from 34.4 to 8.4 events per hour, and average nightly usage of 5.9 hours. Data from the ADHERE registry, which followed 5,000 patients, showed a 62% median reduction in AHI and strong long-term adherence. Shares of Inspire Medical have gained 2.9% since the announcement, though they have declined 53.8% year-to-date.
Zacks Investment Research·65dRead more ▾